Testing Centers for Evaluation of Somatic Cell Genome Editing Approaches for Translational Applications (U42 Clinical Trial Not Allowed)
Forecast
National Institutes of Health plans to offer grants of up to $900,000 (at least $580,000) to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expects to make about 3 awards. It is a forecast: the notice is expected around November 25, 2027, with applications due around January 25, 2028.
From the official notice on Grants.gov, last changed October 13, 2026. Checked October 31, 2026.
- Award ceiling$900,000
- Award floor$580,000
- Expected awards3
- Total fundingnot stated
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Forecast posted | October 13, 2026 |
|---|---|
| Expected posting | November 25, 2027 |
| Expected deadline | January 25, 2028 |
| Expected award date | July 30, 2028 |
Add the deadline to your calendar
Who can apply
This opportunity is open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations.
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
This Notice of Funding Opportunity (NOFO) invites applicants to support Testing Centers for Evaluation of Somatic Cell Genome Editing Approaches for Translational Applications. Each center will provide resources and testing services to the growing community, developing new genome editing technologies and conducting preclinical testing based on these technologies for therapeutics for human diseases. The testing centers will work with NIH-funded investigators to assess the efficacy and safety of genome editing and delivery technologies, determine genome editing thresholds for specific diseases associated with minimal off-target effects, and ascertain feasibility parameters in model systems. This NOFO is especially interested in the application of new approach methodologies (NAMs) to complement traditional in vivo models for the purposes described in this announcement. Research Initiative Details The Testing Centers will establish in vivo and in vitro research models applicable to human health and disease, including NAMs and human-biology-based models. The Testing Centers will develop assays and Standard Operating Procedures (SOPs) for evaluating new genome editing technologies. Data generated by the Centers will help determine whether a treatment strategy using a specific set of tools is effective, has an acceptable safety profile, or requires significant improvement in editing efficacy and specificity. Although each Testing Center will work on a limited number of focused projects, the program and pipeline(s) developed are expected to support multifaceted research activities, build core model systems that can be adapted to accommodate a broad spectrum of diseases, and provide fee-for-service resources to the wider biomedical community on a local, regional, and national basis. The goal of projects supported by this NOFO is to provide research resources that facilitate optimization and enhance scientific rigor, transparency, and experimental reproducibility in biomedical research.
How to apply
- Read the full notice and attachments on Grants.gov. The notice is the official source for deadlines and requirements.
- Make sure your organization has an active SAM.gov registration and Unique Entity ID; registration can take several weeks.
- Register on Grants.gov and submit through Workspace before the deadline and time given in the notice. Our application guide walks through each step.
Questions go to Division of Comparative Medicine, ORIPDCM@mail.nih.gov, 301-435-0744.
Questions people ask
Who can apply for Testing Centers for Evaluation of Somatic Cell Genome Editing Approaches for Translational Applications (U42 Clinical Trial Not Allowed)?
National Institutes of Health accepts applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Testing Centers for Evaluation of Somatic Cell Genome Editing Approaches for Translational Applications (U42 Clinical Trial Not Allowed)?
Expected deadline January 25, 2028. Confirm the date and time in the official notice on Grants.gov.
How much funding is available?
Awards of up to $900,000 each.
Similar open grants
- Continuation of the Collaborative Islet Transplantation Registry (U01 Clinical Trial Not allowed)
- BRAIN Initiative Cell Atlas Network (BICAN): Coordinating Unit for Biostatistics, Informatics, and Engagement (CUBIE)
- Centers without Walls for mechanisms of neurodegeneration in Alzheimer’s disease-related dementias (ADRD)
- Expanding the Therapeutic Pipeline for Treating and Preventing Alzheimer's Disease and Related Dementias: Preclinical Validation and Drug Discovery for Novel Candidate Targets (U01 Clinical Trial Not Allowed)
- Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE, RP1 Clinical Trial Not Allowed)
- Exposomic Contributions to ADRD Pathology and Resilience